Last edition
News about "depemokimab"
GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP
European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.
Depemokimab | 18/02/2026 | By News Bureau
Japan Approves Exdensur for Severe Asthma and Nasal Polyps
Japan has approved Exdensur (depemokimab) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic in the country, with approval supported by phase-III SWIFT and ANCHOR trial data demonstrating sustained efficacy with twice-yearly dosing.
Depemokimab | 07/01/2026 | By News Bureau | 226
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy